Partner Headlines - NPSP

  1. NPS Pharmaceuticals Chief: Why 250k-a-Year Orphan Drug ...

    YCharts

  2. You Can Expect More Insider Trading in Pharma Stocks: ...

    YCharts

  3. FDA Approves NPS Gattex for Injection for Some SBS Patients

    Benzinga

  4. NPS Pharma Shares Moving Lower Amid FDA Approval of Gattex

    Benzinga

  5. NPS Pharma Publishes Pivotal Phase 3 Study of Gattex in ...

    Benzinga

  6. NPS Pharmaceuticals Inc. Reports Operating Results (10-Q)

    GuruFocus

  7. Benzinga Mid-Afternoon Market Update

    Benzinga

  8. Benzinga Mid-Day Market Update

    Benzinga

  9. Benzinga Mid-Morning Market Update

    Benzinga

  10. UPDATE: Jefferies & Company Reiterates Buy Rating, ...

    Benzinga

  11. FDA Advisory Committee Unanimously Recommends Approval ...

    Benzinga

  12. Benzinga Mid-Day Market Update

    Benzinga

  13. Benzinga Mid-Afternoon Market Update

    Benzinga

  14. Benzinga Mid-Morning Market Update

    Benzinga

  15. UPDATE: Morgan Stanley Initiates NPS Pharmaceuticals at ...

    Benzinga

  16. Benzinga's Top Pre-Market Gainers

    Benzinga

  17. NPS Pharma Expects to File Natpara BLA in Mid 2013

    Benzinga

  18. Revestive Receives European Marketing Authorization for ...

    Benzinga

  19. NPS Pharma Says Gattex Meeting October 16th

    Benzinga

  20. Biotechs With Upcoming PDUFA Dates

    Benzinga

  21. NPS Pharmaceuticals (NPSP) Gains 10.8% as Short Bowel ...

    At Market Intelligence Center

  22. Social Media Outlook for Friday June 22 (DRI, NPSP, R, GS)

    Benzinga

  23. Benzinga's Top Pre-Market Gainers

    Benzinga

  24. NPS Pharmaceuticals Reports NatparaTM Phase 3 Results to ...

    Benzinga

  25. NPS Pharmaceuticals Inc. Reports Operating Results (10-K)

    at GuruFocus

  26. Benzinga's Top Pre-Market Gainers

    at Benzinga

  27. Notable Call Options Activity in NPS Pharmaceuticals

    at Benzinga

  28. Put Volume Surges on Plunging NPS Pharmaceuticals

    By SchaeffersResearch
Marketplace
Trading Center